Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Other Non Operating Income (2016 - 2025)

Voyager Therapeutics' Other Non Operating Income history spans 10 years, with the latest figure at $404000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income changed 0.5% to $404000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 165.11% increase, with the full-year FY2025 number at $1.6 million, up 165.11% from a year prior.
  • Other Non Operating Income hit $404000.0 in Q4 2025 for Voyager Therapeutics, up from $400000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for VYGR hit a ceiling of $3.9 million in Q1 2021 and a floor of -$1.6 million in Q2 2021.
  • Historically, Other Non Operating Income has averaged $521666.7 across 5 years, with a median of $400000.0 in 2025.
  • Biggest five-year swings in Other Non Operating Income: tumbled 3341.3% in 2021 and later skyrocketed 2454.46% in 2022.
  • Tracing VYGR's Other Non Operating Income over 5 years: stood at $650000.0 in 2021, then crashed by 103.54% to -$23000.0 in 2022, then surged by 113.04% to $3000.0 in 2023, then skyrocketed by 13300.0% to $402000.0 in 2024, then increased by 0.5% to $404000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for VYGR at $404000.0 in Q4 2025, $400000.0 in Q3 2025, and $427000.0 in Q2 2025.